Global Neurology Clinical Trial Market 2023 by Company, Regions, Type and Application, Forecast to 2029

1 Market Overview

• 1.1 Product Overview and Scope of Neurology Clinical Trial
• 1.2 Market Estimation Caveats and Base Year
• 1.3 Classification of Neurology Clinical Trial by Type
  • 1.3.1 Overview: Global Neurology Clinical Trial Market Size by Type: 2018 Versus 2022 Versus 2029
  • 1.3.2 Global Neurology Clinical Trial Consumption Value Market Share by Type in 2022
  • 1.3.3 Bone Marrow
  • 1.3.4 Epidermis
  • 1.3.5 Mesenchymal Stem Cells
  • 1.3.6 Haematopoietic Stem Cells
  • 1.3.7 Chondrocytes
• 1.4 Global Neurology Clinical Trial Market by Application
  • 1.4.1 Overview: Global Neurology Clinical Trial Market Size by Application: 2018 Versus 2022 Versus 2029
  • 1.4.2 Neurodegenerative Disorders
  • 1.4.3 Cardiovascular Disorders
  • 1.4.4 Orthopedics
  • 1.4.5 Wound Healing
  • 1.4.6 Other
• 1.5 Global Neurology Clinical Trial Market Size & Forecast
• 1.6 Global Neurology Clinical Trial Market Size and Forecast by Region
  • 1.6.1 Global Neurology Clinical Trial Market Size by Region: 2018 VS 2022 VS 2029
  • 1.6.2 Global Neurology Clinical Trial Market Size by Region, (2018-2029)
  • 1.6.3 North America Neurology Clinical Trial Market Size and Prospect (2018-2029)
  • 1.6.4 Europe Neurology Clinical Trial Market Size and Prospect (2018-2029)
  • 1.6.5 Asia-Pacific Neurology Clinical Trial Market Size and Prospect (2018-2029)
  • 1.6.6 South America Neurology Clinical Trial Market Size and Prospect (2018-2029)
  • 1.6.7 Middle East and Africa Neurology Clinical Trial Market Size and Prospect (2018-2029)

2 Company Profiles

• 2.1 BrainStorm Cell Therapeutics
  • 2.1.1 BrainStorm Cell Therapeutics Details
  • 2.1.2 BrainStorm Cell Therapeutics Major Business
  • 2.1.3 BrainStorm Cell Therapeutics Neurology Clinical Trial Product and Solutions
  • 2.1.4 BrainStorm Cell Therapeutics Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.1.5 BrainStorm Cell Therapeutics Recent Developments and Future Plans
• 2.2 Opexa Therapeutics
  • 2.2.1 Opexa Therapeutics Details
  • 2.2.2 Opexa Therapeutics Major Business
  • 2.2.3 Opexa Therapeutics Neurology Clinical Trial Product and Solutions
  • 2.2.4 Opexa Therapeutics Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.2.5 Opexa Therapeutics Recent Developments and Future Plans
• 2.3 Caladrius Biosciences
  • 2.3.1 Caladrius Biosciences Details
  • 2.3.2 Caladrius Biosciences Major Business
  • 2.3.3 Caladrius Biosciences Neurology Clinical Trial Product and Solutions
  • 2.3.4 Caladrius Biosciences Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.3.5 Caladrius Biosciences Recent Developments and Future Plans
• 2.4 U.S. Stem Cell
  • 2.4.1 U.S. Stem Cell Details
  • 2.4.2 U.S. Stem Cell Major Business
  • 2.4.3 U.S. Stem Cell Neurology Clinical Trial Product and Solutions
  • 2.4.4 U.S. Stem Cell Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.4.5 U.S. Stem Cell Recent Developments and Future Plans
• 2.5 Lonza
  • 2.5.1 Lonza Details
  • 2.5.2 Lonza Major Business
  • 2.5.3 Lonza Neurology Clinical Trial Product and Solutions
  • 2.5.4 Lonza Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.5.5 Lonza Recent Developments and Future Plans
• 2.6 Bristol Myers Squibb
  • 2.6.1 Bristol Myers Squibb Details
  • 2.6.2 Bristol Myers Squibb Major Business
  • 2.6.3 Bristol Myers Squibb Neurology Clinical Trial Product and Solutions
  • 2.6.4 Bristol Myers Squibb Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.6.5 Bristol Myers Squibb Recent Developments and Future Plans
• 2.7 Corning Incorporated
  • 2.7.1 Corning Incorporated Details
  • 2.7.2 Corning Incorporated Major Business
  • 2.7.3 Corning Incorporated Neurology Clinical Trial Product and Solutions
  • 2.7.4 Corning Incorporated Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.7.5 Corning Incorporated Recent Developments and Future Plans
• 2.8 Vericel Corporation
  • 2.8.1 Vericel Corporation Details
  • 2.8.2 Vericel Corporation Major Business
  • 2.8.3 Vericel Corporation Neurology Clinical Trial Product and Solutions
  • 2.8.4 Vericel Corporation Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.8.5 Vericel Corporation Recent Developments and Future Plans
• 2.9 Catalent
  • 2.9.1 Catalent Details
  • 2.9.2 Catalent Major Business
  • 2.9.3 Catalent Neurology Clinical Trial Product and Solutions
  • 2.9.4 Catalent Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.9.5 Catalent Recent Developments and Future Plans
• 2.10 Lineage Cell Therapeutics
  • 2.10.1 Lineage Cell Therapeutics Details
  • 2.10.2 Lineage Cell Therapeutics Major Business
  • 2.10.3 Lineage Cell Therapeutics Neurology Clinical Trial Product and Solutions
  • 2.10.4 Lineage Cell Therapeutics Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.10.5 Lineage Cell Therapeutics Recent Developments and Future Plans
• 2.11 Castle Creek Biosciences
  • 2.11.1 Castle Creek Biosciences Details
  • 2.11.2 Castle Creek Biosciences Major Business
  • 2.11.3 Castle Creek Biosciences Neurology Clinical Trial Product and Solutions
  • 2.11.4 Castle Creek Biosciences Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.11.5 Castle Creek Biosciences Recent Developments and Future Plans
• 2.12 Sangamo Therapeutics
  • 2.12.1 Sangamo Therapeutics Details
  • 2.12.2 Sangamo Therapeutics Major Business
  • 2.12.3 Sangamo Therapeutics Neurology Clinical Trial Product and Solutions
  • 2.12.4 Sangamo Therapeutics Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.12.5 Sangamo Therapeutics Recent Developments and Future Plans
• 2.13 Novartis
  • 2.13.1 Novartis Details
  • 2.13.2 Novartis Major Business
  • 2.13.3 Novartis Neurology Clinical Trial Product and Solutions
  • 2.13.4 Novartis Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.13.5 Novartis Recent Developments and Future Plans
• 2.14 Holostem Terapie Avanzate S.R.L
  • 2.14.1 Holostem Terapie Avanzate S.R.L Details
  • 2.14.2 Holostem Terapie Avanzate S.R.L Major Business
  • 2.14.3 Holostem Terapie Avanzate S.R.L Neurology Clinical Trial Product and Solutions
  • 2.14.4 Holostem Terapie Avanzate S.R.L Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.14.5 Holostem Terapie Avanzate S.R.L Recent Developments and Future Plans
• 2.15 Pharmicell
  • 2.15.1 Pharmicell Details
  • 2.15.2 Pharmicell Major Business
  • 2.15.3 Pharmicell Neurology Clinical Trial Product and Solutions
  • 2.15.4 Pharmicell Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.15.5 Pharmicell Recent Developments and Future Plans
• 2.16 Tego Science
  • 2.16.1 Tego Science Details
  • 2.16.2 Tego Science Major Business
  • 2.16.3 Tego Science Neurology Clinical Trial Product and Solutions
  • 2.16.4 Tego Science Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.16.5 Tego Science Recent Developments and Future Plans
• 2.17 Autolus therapeutics
  • 2.17.1 Autolus therapeutics Details
  • 2.17.2 Autolus therapeutics Major Business
  • 2.17.3 Autolus therapeutics Neurology Clinical Trial Product and Solutions
  • 2.17.4 Autolus therapeutics Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.17.5 Autolus therapeutics Recent Developments and Future Plans
• 2.18 Bayer AG
  • 2.18.1 Bayer AG Details
  • 2.18.2 Bayer AG Major Business
  • 2.18.3 Bayer AG Neurology Clinical Trial Product and Solutions
  • 2.18.4 Bayer AG Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.18.5 Bayer AG Recent Developments and Future Plans
• 2.19 Sartorius AG
  • 2.19.1 Sartorius AG Details
  • 2.19.2 Sartorius AG Major Business
  • 2.19.3 Sartorius AG Neurology Clinical Trial Product and Solutions
  • 2.19.4 Sartorius AG Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.19.5 Sartorius AG Recent Developments and Future Plans
• 2.20 Daiichi Sankyo
  • 2.20.1 Daiichi Sankyo Details
  • 2.20.2 Daiichi Sankyo Major Business
  • 2.20.3 Daiichi Sankyo Neurology Clinical Trial Product and Solutions
  • 2.20.4 Daiichi Sankyo Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.20.5 Daiichi Sankyo Recent Developments and Future Plans
• 2.21 Takeda Pharmaceutical Company
  • 2.21.1 Takeda Pharmaceutical Company Details
  • 2.21.2 Takeda Pharmaceutical Company Major Business
  • 2.21.3 Takeda Pharmaceutical Company Neurology Clinical Trial Product and Solutions
  • 2.21.4 Takeda Pharmaceutical Company Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.21.5 Takeda Pharmaceutical Company Recent Developments and Future Plans
• 2.22 Sumitomo Chemical Co
  • 2.22.1 Sumitomo Chemical Co Details
  • 2.22.2 Sumitomo Chemical Co Major Business
  • 2.22.3 Sumitomo Chemical Co Neurology Clinical Trial Product and Solutions
  • 2.22.4 Sumitomo Chemical Co Neurology Clinical Trial Revenue, Gross Margin and Market Share (2018-2023)
  • 2.22.5 Sumitomo Chemical Co Recent Developments and Future Plans

3 Market Competition, by Players

• 3.1 Global Neurology Clinical Trial Revenue and Share by Players (2018-2023)
• 3.2 Market Share Analysis (2022)
  • 3.2.1 Market Share of Neurology Clinical Trial by Company Revenue
  • 3.2.2 Top 3 Neurology Clinical Trial Players Market Share in 2022
  • 3.2.3 Top 6 Neurology Clinical Trial Players Market Share in 2022
• 3.3 Neurology Clinical Trial Market: Overall Company Footprint Analysis
  • 3.3.1 Neurology Clinical Trial Market: Region Footprint
  • 3.3.2 Neurology Clinical Trial Market: Company Product Type Footprint
  • 3.3.3 Neurology Clinical Trial Market: Company Product Application Footprint
• 3.4 New Market Entrants and Barriers to Market Entry
• 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

• 4.1 Global Neurology Clinical Trial Consumption Value and Market Share by Type (2018-2023)
• 4.2 Global Neurology Clinical Trial Market Forecast by Type (2024-2029)

5 Market Size Segment by Application

• 5.1 Global Neurology Clinical Trial Consumption Value Market Share by Application (2018-2023)
• 5.2 Global Neurology Clinical Trial Market Forecast by Application (2024-2029)

6 North America

• 6.1 North America Neurology Clinical Trial Consumption Value by Type (2018-2029)
• 6.2 North America Neurology Clinical Trial Consumption Value by Application (2018-2029)
• 6.3 North America Neurology Clinical Trial Market Size by Country
  • 6.3.1 North America Neurology Clinical Trial Consumption Value by Country (2018-2029)
  • 6.3.2 United States Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 6.3.3 Canada Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 6.3.4 Mexico Neurology Clinical Trial Market Size and Forecast (2018-2029)

7 Europe

• 7.1 Europe Neurology Clinical Trial Consumption Value by Type (2018-2029)
• 7.2 Europe Neurology Clinical Trial Consumption Value by Application (2018-2029)
• 7.3 Europe Neurology Clinical Trial Market Size by Country
  • 7.3.1 Europe Neurology Clinical Trial Consumption Value by Country (2018-2029)
  • 7.3.2 Germany Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 7.3.3 France Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 7.3.4 United Kingdom Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 7.3.5 Russia Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 7.3.6 Italy Neurology Clinical Trial Market Size and Forecast (2018-2029)

8 Asia-Pacific

• 8.1 Asia-Pacific Neurology Clinical Trial Consumption Value by Type (2018-2029)
• 8.2 Asia-Pacific Neurology Clinical Trial Consumption Value by Application (2018-2029)
• 8.3 Asia-Pacific Neurology Clinical Trial Market Size by Region
  • 8.3.1 Asia-Pacific Neurology Clinical Trial Consumption Value by Region (2018-2029)
  • 8.3.2 China Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 8.3.3 Japan Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 8.3.4 South Korea Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 8.3.5 India Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 8.3.6 Southeast Asia Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 8.3.7 Australia Neurology Clinical Trial Market Size and Forecast (2018-2029)

9 South America

• 9.1 South America Neurology Clinical Trial Consumption Value by Type (2018-2029)
• 9.2 South America Neurology Clinical Trial Consumption Value by Application (2018-2029)
• 9.3 South America Neurology Clinical Trial Market Size by Country
  • 9.3.1 South America Neurology Clinical Trial Consumption Value by Country (2018-2029)
  • 9.3.2 Brazil Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 9.3.3 Argentina Neurology Clinical Trial Market Size and Forecast (2018-2029)

10 Middle East & Africa

• 10.1 Middle East & Africa Neurology Clinical Trial Consumption Value by Type (2018-2029)
• 10.2 Middle East & Africa Neurology Clinical Trial Consumption Value by Application (2018-2029)
• 10.3 Middle East & Africa Neurology Clinical Trial Market Size by Country
  • 10.3.1 Middle East & Africa Neurology Clinical Trial Consumption Value by Country (2018-2029)
  • 10.3.2 Turkey Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 10.3.3 Saudi Arabia Neurology Clinical Trial Market Size and Forecast (2018-2029)
  • 10.3.4 UAE Neurology Clinical Trial Market Size and Forecast (2018-2029)

11 Market Dynamics

• 11.1 Neurology Clinical Trial Market Drivers
• 11.2 Neurology Clinical Trial Market Restraints
• 11.3 Neurology Clinical Trial Trends Analysis
• 11.4 Porters Five Forces Analysis
  • 11.4.1 Threat of New Entrants
  • 11.4.2 Bargaining Power of Suppliers
  • 11.4.3 Bargaining Power of Buyers
  • 11.4.4 Threat of Substitutes
  • 11.4.5 Competitive Rivalry
• 11.5 Influence of COVID-19 and Russia-Ukraine War
  • 11.5.1 Influence of COVID-19
  • 11.5.2 Influence of Russia-Ukraine War

12 Industry Chain Analysis

• 12.1 Neurology Clinical Trial Industry Chain
• 12.2 Neurology Clinical Trial Upstream Analysis
• 12.3 Neurology Clinical Trial Midstream Analysis
• 12.4 Neurology Clinical Trial Downstream Analysis

13 Research Findings and Conclusion

14 Appendix

• 14.1 Methodology
• 14.2 Research Process and Data Source